Checkpoint inhibitors like nivolumab and relatlimab act by removing ... is one of the drugs intended to step into its shoes after biosimilar competition starts – the failed trial comes as ...

It's worth noting also that Yervoy is not too far away from patent expiry, so Opdualag will help bolster BMS' cancer immunotherapy franchise once biosimilar rivals reach the market. BMS has high ...

(Jan. 2 issue), 1 the combination of nivolumab and ipilimumab resulted in an unprecedented increase in overall and melanoma-specific survival, as compared with ipilimumab alone. We should be wary ...

Nemvaleukin/pembrolizumab did not achieve a statistically significant improvement in OS vs investigator’s choice chemotherapy alone in the interim analysis. The ...

SHANGHAI, China I March 23, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of a new Opdivo® (nivolumab ...

There were 11 hypersensitivity reactions, all in patients receiving nivolumab. Reducing the infusion time for nivolumab and pembrolizumab to 10 minutes is feasible and safe, according to researchers.

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to biosimilars and new options enter the market. Immunology physicians are starting ...

WARMINSTER, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel in macular telangiectasia type 2 (MacTel), as well as the importance of ...